Q1 EPS Estimate for United Therapeutics Decreased by Analyst

United Therapeutics Co. (NASDAQ:UTHR) – Equities research analysts at Zacks Research lowered their Q1 2025 earnings per share estimates for shares of United Therapeutics in a research note issued to investors on Monday, March 17th. Zacks Research analyst R. Department now expects that the biotechnology company will post earnings per share of $6.36 for the quarter, down from their prior estimate of $6.93. The consensus estimate for United Therapeutics’ current full-year earnings is $24.48 per share. Zacks Research also issued estimates for United Therapeutics’ Q2 2025 earnings at $6.71 EPS, Q3 2025 earnings at $6.95 EPS, Q4 2025 earnings at $6.68 EPS, FY2025 earnings at $26.69 EPS, Q1 2026 earnings at $6.48 EPS, Q2 2026 earnings at $6.76 EPS, Q3 2026 earnings at $7.12 EPS, Q4 2026 earnings at $7.36 EPS, FY2026 earnings at $27.73 EPS and FY2027 earnings at $28.24 EPS.

A number of other equities research analysts also recently weighed in on the company. UBS Group boosted their price target on United Therapeutics from $415.00 to $475.00 and gave the company a “buy” rating in a report on Wednesday, January 8th. StockNews.com lowered United Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Thursday, February 27th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $425.00 target price on shares of United Therapeutics in a research report on Thursday, February 27th. One research analyst has rated the stock with a sell rating, two have given a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $388.25.

United Therapeutics Stock Down 1.6 %

UTHR stock opened at $313.60 on Wednesday. United Therapeutics has a 52-week low of $221.53 and a 52-week high of $417.82. The stock’s 50 day moving average is $346.14 and its two-hundred day moving average is $357.34. The company has a market capitalization of $14.08 billion, a PE ratio of 13.77, a P/E/G ratio of 0.97 and a beta of 0.64.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, February 26th. The biotechnology company reported $6.19 EPS for the quarter, topping the consensus estimate of $6.10 by $0.09. The firm had revenue of $735.90 million for the quarter, compared to analyst estimates of $734.74 million. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. During the same period in the previous year, the company posted $4.36 EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in UTHR. Wealthfront Advisers LLC boosted its position in shares of United Therapeutics by 2,090,573.5% in the 4th quarter. Wealthfront Advisers LLC now owns 18,314,300 shares of the biotechnology company’s stock worth $6,462,018,000 after purchasing an additional 18,313,424 shares during the last quarter. Norges Bank bought a new position in United Therapeutics during the fourth quarter worth about $151,764,000. FMR LLC lifted its holdings in United Therapeutics by 36.5% during the fourth quarter. FMR LLC now owns 1,471,405 shares of the biotechnology company’s stock worth $519,170,000 after acquiring an additional 393,777 shares in the last quarter. World Investment Advisors LLC acquired a new stake in shares of United Therapeutics in the 3rd quarter valued at about $139,206,000. Finally, Thrivent Financial for Lutherans raised its stake in shares of United Therapeutics by 1,325.5% in the 4th quarter. Thrivent Financial for Lutherans now owns 204,299 shares of the biotechnology company’s stock valued at $72,085,000 after purchasing an additional 189,967 shares during the period. 94.08% of the stock is currently owned by institutional investors.

Insider Buying and Selling at United Therapeutics

In other news, Director Nilda Mesa sold 255 shares of the firm’s stock in a transaction on Monday, December 30th. The stock was sold at an average price of $355.77, for a total value of $90,721.35. Following the transaction, the director now directly owns 5,528 shares in the company, valued at $1,966,696.56. This trade represents a 4.41 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Michael Benkowitz sold 10,000 shares of the firm’s stock in a transaction on Monday, February 24th. The stock was sold at an average price of $360.76, for a total value of $3,607,600.00. Following the completion of the transaction, the chief operating officer now owns 2,577 shares in the company, valued at $929,678.52. This represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 90,255 shares of company stock valued at $32,614,521 in the last quarter. Corporate insiders own 11.90% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.